The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.

Authors:
Gallipoli P; Clark RE; Byrne J; Apperley JF; Milojkovic D and 3 more

Journal:
Br J Haematol

Publication Year: 2022

DOI:
10.1111/bjh.17961

PMCID:
PMC7613110

PMID:
34993961

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Haematol

Abbreviation: Br J Haematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of foamy macrophages in the bone marrow following chronic intravenous drug use.
Kyla Y; Penelope K; Kerry BM and 1 more (2022) - Transparency Score: 1/6
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with elt…
Al-Samkari H; Jiang D; Gernsheimer T and 5 more (2022) - Transparency Score: 3/6
Antithrombin-III mitigates thrombin-mediated endothelial cell contraction and sickle red blood cell…
Wulftange WJ; Kucukal E; Man Y and 10 more (2022) - Transparency Score: 4/6
A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute l…
Andersson NG; Rathe M; Mølle I and 12 more (2022) - Transparency Score: 3/6
BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
Branford S. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest: REC declares research support and honoraria from Novartis and Bristol Myers Squibb, and honoraria from Pfizer in the past 3 years. JB declares research support and honoraria from Novartis, Pfizer and Incyte over the past 3 years. JFA declares research support and honoraria from Novartis, Incyte and Pfizer. DM declares research support and honoraria from Novartis, Bristol Myers Squibb, Incyte and BMS."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025